Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a
clinical stage biotechnology company developing regenerated organs for
transplant, initially focused on the trachea, will announce results of
its second quarter ended June 30, 2014 before market trading hours on
Friday, August 8, 2014. A conference call to discuss the company's
second quarter results and the company's operations is scheduled for
that same day at 11:00 AM (Eastern Time). On that call, management may
take questions from the audience on any of a number of topics related to
the business, including operations, plans and outlook.
Investors can access the live conferece call by dialing the following
phone numbers: toll-free 888-455-2260, or toll/international:
719-325-2484, and referencing the pass code "9685223".
If you are unable to listen to the live conference call, a replay will
be available from approximately 2:00 PM (Eastern Time) on August 8, 2014
through 2:00 PM (Eastern Time) on August 15, 2014 and will be accessible
by dialing toll-free 888-203-1112, or toll/international 719-457-0820,
and referencing the pass code "9685223".
About Harvard Apparatus Regenerative Technology
Harvard Apparatus Regenerative Technology makes regenerated organs for
transplant. Our first product, the HART-Trachea, is intended to replace
or repair a trachea that has been severely damaged by either trachea
cancer or physical trauma. Our technology has been used in eight human
trachea transplants to date approved under compassionate use exemptions,
but none of our products are yet approved by a government regulatory
authority for marketing. On November 1, 2013, HART was spun-off from
Harvard Bioscience. The trademark "Harvard Apparatus" is used under a
sublicense agreement with Harvard Bioscience, who has licensed the right
to use such trademark from Harvard University.
[ Back To NFVZone's Homepage ]